These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Adrenergic beta-blocker medication, formally contraindicated in all forms of diabetes mellitus?]. Tacu V; Blum M; Tudor G; Mandric E Rev Med Chir Soc Med Nat Iasi; 1984; 88(3):535-9. PubMed ID: 6152746 [No Abstract] [Full Text] [Related]
24. Follow-up of intensive glucose control in type 2 diabetes. Cruickshank JM N Engl J Med; 2009 Jan; 360(4):417-8; author reply 418. PubMed ID: 19172673 [No Abstract] [Full Text] [Related]
25. [Is it necessary to systematically treat diabetics with ACE inhibitors?]. Marre M; Collet C; Stevenin C Journ Annu Diabetol Hotel Dieu; 2001; ():185-7. PubMed ID: 11565461 [No Abstract] [Full Text] [Related]
26. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study Group BMJ; 1998 Sep; 317(7160):703-13. PubMed ID: 9732337 [TBL] [Abstract][Full Text] [Related]
27. Cardiovascular therapies and risk for development of diabetes. Pepine CJ; Cooper-Dehoff RM J Am Coll Cardiol; 2004 Aug; 44(3):509-12. PubMed ID: 15358012 [TBL] [Abstract][Full Text] [Related]
29. [Are the newer antihypertensive agents better and more effective than diuretics?]. Landmark K Tidsskr Nor Laegeforen; 2001 Feb; 121(6):701-5. PubMed ID: 11293353 [TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study Group BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339 [TBL] [Abstract][Full Text] [Related]
31. [Old or new antihypertensives--which are better?]. Schrader J; Kulschewski A MMW Fortschr Med; 2005 Mar; 147(13):36-7, 39-40. PubMed ID: 15832760 [TBL] [Abstract][Full Text] [Related]
32. Management of high blood pressure in diabetes mellitus: lessons from The ADA Recommendation. Waspadji S Acta Med Indones; 2004; 36(1):31-5. PubMed ID: 15673934 [No Abstract] [Full Text] [Related]
34. The management of the diabetic patient with prior cardiovascular events. Fonarow GC Rev Cardiovasc Med; 2003; 4 Suppl 6():S38-49. PubMed ID: 14668702 [TBL] [Abstract][Full Text] [Related]
35. Blood pressure reduction is not the only determinant of outcome. Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926 [No Abstract] [Full Text] [Related]
36. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338 [TBL] [Abstract][Full Text] [Related]
37. Selecting antihypertensive medication in patients with essential hypertension in Malaysia. Ong HT; Rozina G Med J Malaysia; 2009 Mar; 64(1):3-11. PubMed ID: 19852313 [No Abstract] [Full Text] [Related]
38. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion? Gulliford MC; Charlton J; Latinovic R J Hum Hypertens; 2005 Feb; 19(2):111-7. PubMed ID: 15361893 [TBL] [Abstract][Full Text] [Related]
39. [Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?]. Coca A; Ruilope LM Med Clin (Barc); 2000 Jul; 115(5):178-80. PubMed ID: 10996874 [No Abstract] [Full Text] [Related]